Oncology Injectable and Infused Medication Enrollment Form

CVS specialty®

Fax Referral To: 1-855-297-1270 **Phone:** 1-888-280-1190
Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927 **NCPDP:** 4026325

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: _____ DOB: _____ Gender: ☐ Male ☐ Female
Address: _____City, State, ZIP Code: _____
Preferred Contact Methods: ☐ Phone (to primary # provided below) ☐ Text (to cell # provided below) ☐ Email (to email provided below)
Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.
Primary Phone: _____ Alternate Phone: _____
Email: _____ Last Four of SSN: _____ Primary Language: _____
Parent/Caregiver/Legal Guardian Name (Last, First): _____Relationship to Patient: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____ State License #: _____
NPI #: _____ DEA #: _____ Group or Hospital: _____
Address: _____ City, State, ZIP Code: _____
Phone: _____ Fax: _____ Contact Person: _____ Contact's Phone: _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____ Ship to: ☐ Patient ☐ Office ☐ Other: _____
Diagnosis (ICD-10):
☐ Code: _____ Description _____ ☐ Code: _____ Description _____
Patient Clinical Information:
Allergies: _____ Weight: _____lb/kg Height: _____in/cm BSA: _____ m^2

Oncology Injectable and Infused Medication Enrollment Form
A-K

Please complete Patient and Prescriber Information

Patient Name: _____Patient DOB: _____Patient Phone:_____

Prescriber Name: _____ Prescriber Phone: _____

5 PRESCRIPTION INFORMATION

Medications:

- ☐ Abraxane (nab-paclitaxel)
- ☐ Adcetris (brentuximab vedotin)
- ☐ Alimta (pemetrexed)
- ☐ Alymsys (bevacizumab-maly)
- ☐ Arranon (nelarabine)
- ☐ Asparlas (calaspargase pegol-mknl)
- ☐ Avastin (bevacizumab)
- ☐ Beleodaq (belinostat)
- ☐ Belrapzo (bendamustine)
- ☐ Bendeka (bendamustine)
- ☐ Besponsa (inotuzumab ozogamicin)
- ☐ BiCNU (carmustine)
- ☐ Bleomycin
- ☐ Camptosar (irinotecan)
- ☐ Carboplatin
- ☐ Cisplatin
- ☐ Cladribine
- ☐ Columvi (glofitamab-gxbm)
- ☐ Cyclophosphamide
- ☐ Cyramza (ramucirumab)
- ☐ Cytarabine
- ☐ Dacarbazine
- ☐ Dactinomycin
- ☐ Darzalex (daratumumab)
- ☐ Darzalex Faspro (daratumumab and hyaluronidase-fihj)
- ☐ Daunorubicin
- ☐ Decitabine
- ☐ Dexrazoxane
- ☐ Docetaxel
- ☐ Doxorubicin
- ☐ Doxorubicin liposomal
- ☐ Elitek (rasburicase)
- ☐ Empliciti (elotuzumab)
- ☐ Enhertu (fam-trastuzumab deruxtecan-nxki)
- ☐ Erbitux (cetuximab)
- ☐ Erwinaze (asparaginase Erwinia chrysanthemi)
- ☐ Etoposide
- ☐ Fludarabine
- ☐ Fluorouracil
- ☐ Gazyva (obinutuzumab)
- ☐ Gemcitabine HCL
- ☐ Herceptin (trastuzumab)
- ☐ Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)
- ☐ Herzuma (trastuzumab-pkrb)
- ☐ Ifosfamide
- ☐ Imfinzi (durvalumab)
- ☐ Imjudo (tremelimumab-actl)
- ☐ Irinotecan
- ☐ Istodax (romidepsin)
- ☐ Ixempra (ixabepilone)
- ☐ Jemperli (dostarlimab-gxly)
- ☐ Jevtana (cabazitaxel)
- ☐ Kadcyla (ado-trastuzumab emtansine)
- ☐ Keytruda (pembrolizumab)
- ☐ Kanjinti (trastuzumab-anns)
- ☐ Kyprolis (carfilzomib)

PRESCRIPTIONS	DRUG NAME/STRENGTH	SIG/DIRECTIONS	QUANTITY/REFILLS
RX 1	☐ Other: _____	☐ Other: _____	Quantity:_____ Refills:_____
RX 2	☐ Other: _____	☐ Other: _____	Quantity:_____ Refills:_____
RX 3	☐ Other: _____	☐ Other: _____	Quantity:_____ Refills:_____

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute **Prescriber's Signature: _____Date: _____**	May Substitute / Product Selection Permitted / Substitution Permissible **Prescriber's Signature: _____Date: _____**

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "**No Substitution**" _____ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Oncology Injectable and Infused Medication Enrollment Form
L-Z

Please complete Patient and Prescriber Information

Patient Name: _____Patient DOB: _____Patient Phone:_____

Prescriber Name: _____ Prescriber Phone: _____

5 PRESCRIPTION INFORMATION

Medications:

- ☐ Leucovorin
- ☐ Levoleucovorin
- ☐ Lunsumio (mosunetuzumab-axgb)
- ☐ Margenza (margetuximab-cmkb)
- ☐ Melphalan
- ☐ Mesna
- ☐ Mitomycin
- ☐ Mvasi (bevacizumab-awwb)
- ☐ Mylotarg (gemtuzumab ozogamicin)
- ☐ Onivyde (irinotecan liposomal)
- ☐ Ontruzant (trastuzumab-dttb)
- ☐ Opdivo (nivolumab)
- ☐ Opdualag (nivolumab and relatimab-rmbw)
- ☐ Oxaliplatin
- ☐ Paclitaxel
- ☐ Padcev (enfortumab vedotin-ejfv)
- ☐ Pamidronate
- ☐ Perjeta (pertuzumab)
- ☐ Phesgo (pertuzumab, trastuzamab, and hyaluronidase-zzxf)
- ☐ Polivy (polatuzumab vedotin-piiq)
- ☐ Portrazza (necitumumab)
- ☐ Poteligeo (mogamulizumab-kpkc)
- ☐ Proleukin (aldesleukin, IL-2)
- ☐ Riabni (rituximab-arrx)
- ☐ Rituxan (rituximab)
- ☐ Rituxan Hycela (rituximab and hyaluronidase human)
- ☐ Ruxience (rituximab-pvvr)
- ☐ Rybrevant (amivantamab-vmjw)
- ☐ Rylaze (asparaginase erwinia chrysanthemi-rywn)
- ☐ Sarclisa (isatuximab-irfc)
- ☐ Sylvant (siltuximab)
- ☐ Tecentriq (atezolizumab)
- ☐ Temsirolimus
- ☐ Thyrogen (thyrotropin alfa)
- ☐ Tice BCG (bacillus calmette-guerin live)
- ☐ Tivdak (tisotumab vedotin-tftv)
- ☐ Topotecan
- ☐ Trazimera (trastuzumab-qyyp)
- ☐ Treanda (bendamustine)
- ☐ Trisenox (arsenic trioxide)
- ☐ Truxima (rituximab-abbs)
- ☐ Valrubicin
- ☐ Vectibix (panitumumab)
- ☐ Vegzelma (bevacizumab-adcd)
- ☐ Velcade (bortezomib)
- ☐ Vidaza (azacitidine)
- ☐ Vinblastine
- ☐ Vincristine
- ☐ Vinorelbine
- ☐ Vyxeos (daunorubicin/cytarabine (liposomal))
- ☐ Xgeva (denosumab)
- ☐ Yervoy (ipilimumab)
- ☐ Yondelis (trabectedin)
- ☐ Zaltrap (ziv-aflibercept)
- ☐ Zepzelca (lurbinectedin)
- ☐ Zirabev (bevacizumab-bvzr)
- ☐ Zoledronic Acid
- ☐ Other: _____

PRESCRIPTIONS	DRUG NAME/STRENGTH	SIG/DIRECTIONS	QUANTITY/REFILLS
RX 1	☐ Other: _____	☐ Other: _____	Quantity:_____ Refills:_____
RX 2	☐ Other: _____	☐ Other: _____	Quantity:_____ Refills:_____
RX 3	☐ Other: _____	☐ Other: _____	Quantity:_____ Refills:_____

☐ Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute **Prescriber's Signature: _____Date: _____**	May Substitute / Product Selection Permitted / Substitution Permissible **Prescriber's Signature: _____Date: _____**

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "**No Substitution**" _____ **ATTN: New York and Iowa providers,** please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.